Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis - Trial NCT06309355
Access comprehensive clinical trial information for NCT06309355 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Timeline & Enrollment
Phase 2
Jun 01, 2024
Jun 01, 2025
Primary Outcome
The primary endpoint will be safety. Specifically, the primary endpoint will be the incidence of treatment-related AEs (TRAEs) through Day 50.
Summary
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical
 ointment in adult patients with mild to moderate atopic dermatitis
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06309355
Non-Device Trial